MX2017015835A - Gel oftalmico de bimatoprost aplicable en gotas. - Google Patents

Gel oftalmico de bimatoprost aplicable en gotas.

Info

Publication number
MX2017015835A
MX2017015835A MX2017015835A MX2017015835A MX2017015835A MX 2017015835 A MX2017015835 A MX 2017015835A MX 2017015835 A MX2017015835 A MX 2017015835A MX 2017015835 A MX2017015835 A MX 2017015835A MX 2017015835 A MX2017015835 A MX 2017015835A
Authority
MX
Mexico
Prior art keywords
amount
weight
gel
viscosity
drippable
Prior art date
Application number
MX2017015835A
Other languages
English (en)
Inventor
Polzer Heinz
Paul Elena Pierre-
Senge Jürgen
Original Assignee
Medproject Pharma Entw Und Vertriebsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medproject Pharma Entw Und Vertriebsgesellschaft Mbh filed Critical Medproject Pharma Entw Und Vertriebsgesellschaft Mbh
Publication of MX2017015835A publication Critical patent/MX2017015835A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La invención se refiere a un gel oftálmico aplicable en gotas, en donde dicho gel tiene una composición que comprende bimatoprost en una cantidad deI 0.003 al 0.03 por ciento en peso, poliacrilato en una cantidad de > 0.2 por ciento en peso, povidona (PVP), dextrano, polietilenglicoles (PEG), carboxi-metil-celulosa (CMC) o poli-(alcohol vinílico) (PVA), en una cantidad del 0.2 al 10 por ciento en peso, un agente isotonizante en una cantidad para producir una osmolalidad de 200 a 400 miliosmoles/kilogramo, una sal para ajustar la viscosidad en una cantidad del 0.05 al 0.4 por ciento en peso, una base en una cantidad para ajustar el pH de 6 a 8, y los excipientes normalmente utilizados en los geles oftálmicos, y que tiene una viscosidad en el intervalo de 200 a 2,000 mPa*s.
MX2017015835A 2015-06-09 2016-06-08 Gel oftalmico de bimatoprost aplicable en gotas. MX2017015835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15171233.8A EP3103439B1 (en) 2015-06-09 2015-06-09 Drippable ophthalmic bimatoprost gel
PCT/EP2016/062990 WO2016198434A1 (en) 2015-06-09 2016-06-08 Drippable ophthalmic bimatoprost gel

Publications (1)

Publication Number Publication Date
MX2017015835A true MX2017015835A (es) 2018-08-15

Family

ID=53298285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015835A MX2017015835A (es) 2015-06-09 2016-06-08 Gel oftalmico de bimatoprost aplicable en gotas.

Country Status (28)

Country Link
US (1) US10314780B2 (es)
EP (2) EP3103439B1 (es)
JP (1) JP6342087B1 (es)
KR (1) KR101889878B1 (es)
CN (1) CN107771074B (es)
AU (1) AU2016277336B2 (es)
BR (1) BR112017026552B1 (es)
CA (1) CA2985897C (es)
CY (1) CY1120883T1 (es)
DK (1) DK3307241T3 (es)
ES (2) ES2747302T3 (es)
HK (1) HK1247118A1 (es)
HR (1) HRP20181840T1 (es)
IL (1) IL256071B (es)
LT (1) LT3307241T (es)
MA (1) MA42290B1 (es)
MX (1) MX2017015835A (es)
PL (2) PL3103439T3 (es)
PT (1) PT3307241T (es)
RS (1) RS57948B1 (es)
RU (1) RU2698456C2 (es)
SA (1) SA517390480B1 (es)
SG (1) SG11201708642VA (es)
SI (1) SI3307241T1 (es)
TN (1) TN2017000445A1 (es)
TR (1) TR201815791T4 (es)
UA (1) UA121139C2 (es)
WO (1) WO2016198434A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
CN110200904B (zh) * 2019-05-27 2021-07-23 上海昊海生物科技股份有限公司 一种降眼压缓释滴眼组合物及其制备方法
US11400100B2 (en) 2019-12-11 2022-08-02 Somerset Therapeutics, Llc. Effective benzalkonium chloride-free bimatoprost ophthalmic compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4209722C3 (de) 1992-03-25 1997-06-19 Medproject Pharma Entwicklungs Tropfbares Gel für die Augenheilkunde
DE10132876A1 (de) * 2001-07-06 2003-01-30 Medproject Pharma Entwicklungs Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US20130245124A1 (en) 2010-07-29 2013-09-19 Allergan, Inc. Preservative free bimatoprost solutions
WO2012163827A2 (en) * 2011-05-27 2012-12-06 Ratiopharm Gmbh Ophthalmic preparation comprising a pgf2alpha analogue
AU2012283895A1 (en) * 2011-07-20 2014-02-06 Allergan, Inc. Fixed dose combination of bimatoprost and brimonidine
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
CN104622798B (zh) * 2014-12-05 2017-12-22 广东东阳光药业有限公司 一种含有他氟前列素的滴眼液及其制备方法

Also Published As

Publication number Publication date
AU2016277336B2 (en) 2018-12-06
CA2985897C (en) 2019-10-01
RU2698456C2 (ru) 2019-08-27
UA121139C2 (uk) 2020-04-10
KR101889878B1 (ko) 2018-08-20
SG11201708642VA (en) 2017-11-29
BR112017026552A2 (pt) 2018-08-14
ES2747302T3 (es) 2020-03-10
BR112017026552B1 (pt) 2023-11-14
CY1120883T1 (el) 2019-12-11
EP3103439A1 (en) 2016-12-14
US10314780B2 (en) 2019-06-11
MA42290A (fr) 2016-12-15
TN2017000445A1 (en) 2019-04-12
MA42290B1 (fr) 2018-11-30
HRP20181840T1 (hr) 2019-01-11
IL256071A (en) 2018-01-31
RS57948B1 (sr) 2019-01-31
ES2703432T3 (es) 2019-03-08
DK3307241T3 (en) 2018-11-05
PL3307241T3 (pl) 2019-03-29
IL256071B (en) 2019-09-26
EP3307241A1 (en) 2018-04-18
JP6342087B1 (ja) 2018-06-13
PT3307241T (pt) 2018-11-26
SA517390480B1 (ar) 2021-03-11
AU2016277336A1 (en) 2017-11-23
KR20170140301A (ko) 2017-12-20
PL3103439T3 (pl) 2019-12-31
EP3307241B8 (en) 2018-12-19
RU2017138099A (ru) 2019-07-10
CN107771074B (zh) 2021-04-02
EP3307241B1 (en) 2018-09-26
RU2017138099A3 (es) 2019-07-17
LT3307241T (lt) 2018-12-10
SI3307241T1 (sl) 2018-12-31
CA2985897A1 (en) 2016-12-15
EP3103439B1 (en) 2019-08-07
US20180228724A1 (en) 2018-08-16
WO2016198434A1 (en) 2016-12-15
CN107771074A (zh) 2018-03-06
TR201815791T4 (tr) 2018-11-21
JP2018518466A (ja) 2018-07-12
HK1247118A1 (zh) 2018-09-21

Similar Documents

Publication Publication Date Title
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
MY197845A (en) Pharmaceutical composition
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
IT1393402B1 (it) Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali
MX2022011896A (es) Composiciones oftalmicas.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12019501639A1 (en) Jaki selective inhibitors
MX2017015835A (es) Gel oftalmico de bimatoprost aplicable en gotas.
IN2013MU03583A (es)
PH12020550608A1 (en) Pyrrole derivatives as acc inhibitors
GB202202470D0 (en) Bio-ink formulations, bio-printed corneal lenticule, and applications thereof
EP3412292A4 (en) USE OF METHOXATIN, DERIVATIVE AND / OR SALT OF SJÖGREN SYNDROME AND PHARMACEUTICAL COMPOSITION
WO2017223261A3 (en) Hydrogels, articles comprising hydrogels, and methods thereof
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
TR201713929A2 (tr) Ki̇tosan ve alji̇natin hemostati̇k kompozi̇syonlari
PH12020550009A1 (en) Pharmaceutical preparation and preparation method therefor
MX2023011670A (es) Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).
MX2018008868A (es) Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso.
WO2015081319A3 (en) Activity enhancing curcumin compositions and methods of use
MX2017002194A (es) Composicion anticorrosion.
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
EP3257881A4 (en) Fluorinated copolymer, and surface modifier containing same as active ingredient

Legal Events

Date Code Title Description
FG Grant or registration